Immuneering (IMRX) Expected to Release Quarterly Earnings on Wednesday

Immuneering (NASDAQ:IMRX – Get Free Report) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect Immuneering to post earnings of ($0.29) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). On average, analysts expect Immuneering to post ($1.19) EPS for the current fiscal year and ($1.58) EPS for the next fiscal year.

Immuneering Trading Down 0.8%

NASDAQ:IMRX opened at $3.65 on Tuesday. The firm has a market cap of $236.37 million, a price-to-earnings ratio of -3.54 and a beta of 0.49. The company’s 50-day moving average is $4.09 and its two-hundred day moving average is $4.77. Immuneering has a 12-month low of $3.35 and a 12-month high of $8.48.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IMRX. Wall Street Zen downgraded shares of Immuneering from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Immuneering in a research report on Friday, October 30th. Mizuho set a $11.00 target price on shares of Immuneering in a research report on Thursday, October 29th. Finally, UBS Group set a $14.00 target price on shares of Immuneering in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.67.

Get Our Latest Analysis on IMRX

About Immuneering

(Get Free Report)

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.

See Also

Earnings History for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.